Mesirow Institutional Investment Management Inc. Has $14.12 Million Stock Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Mesirow Institutional Investment Management Inc. reduced its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 8.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 380,389 shares of the company's stock after selling 33,560 shares during the quarter. Mesirow Institutional Investment Management Inc. owned approximately 0.79% of Amphastar Pharmaceuticals worth $14,124,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Smartleaf Asset Management LLC boosted its position in shares of Amphastar Pharmaceuticals by 222.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock worth $26,000 after purchasing an additional 493 shares in the last quarter. Parkside Financial Bank & Trust raised its stake in shares of Amphastar Pharmaceuticals by 806.5% in the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock valued at $36,000 after purchasing an additional 871 shares during the period. Huntington National Bank lifted its holdings in shares of Amphastar Pharmaceuticals by 36.9% in the fourth quarter. Huntington National Bank now owns 1,340 shares of the company's stock valued at $50,000 after purchasing an additional 361 shares in the last quarter. TD Private Client Wealth LLC boosted its position in shares of Amphastar Pharmaceuticals by 22.7% during the fourth quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company's stock worth $78,000 after buying an additional 388 shares during the period. Finally, KBC Group NV grew its holdings in shares of Amphastar Pharmaceuticals by 43.1% during the fourth quarter. KBC Group NV now owns 2,159 shares of the company's stock worth $80,000 after buying an additional 650 shares in the last quarter. Institutional investors and hedge funds own 65.09% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Piper Sandler lowered their price target on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research note on Friday, March 21st. Needham & Company LLC reissued a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th.

Amphastar Pharmaceuticals Stock Performance

Shares of Amphastar Pharmaceuticals stock traded up $0.10 during trading on Friday, reaching $24.17. The company's stock had a trading volume of 94,575 shares, compared to its average volume of 608,776. Amphastar Pharmaceuticals, Inc. has a 52 week low of $22.64 and a 52 week high of $53.96. The firm has a market cap of $1.15 billion, a PE ratio of 8.05, a P/E/G ratio of 2.19 and a beta of 0.79. The business's 50-day moving average price is $27.17 and its 200-day moving average price is $36.73. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82.

Insider Activity at Amphastar Pharmaceuticals

In related news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the transaction, the chief financial officer now directly owns 97,363 shares of the company's stock, valued at $2,681,377.02. This trade represents a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 27.10% of the stock is currently owned by corporate insiders.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.